Exploring the Efficacy and Risks of Karaprazine in Depression Treatment

This chapter delves into the FDA-approved drug Karaprazine, discussing its mechanism of action, effectiveness in bipolar illness, and potential as a monotherapy for depression. It compares the significant antidepressant and anti-manic effects of Karaprazine with other medications, highlighting the risks associated with certain drugs and the controversy surrounding SSRIs. The chapter also examines strategies for enhancing antidepressant response times, including combining antidepressants with antipsychotics and the considerations involved in this approach.